Company news
Viridian Therapeutics, Inc. news in 2020
Viridian Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease
December 16, 2020
miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
November 9, 2020
miRagen Announces Internal Review of Preliminary Topline Data for the Phase 2 SOLAR Clinical Trial of Cobomarsen in Patients with Cutaneous T-Cell Lymphoma (CTCL)
October 4, 2020
miRagen Announces Leadership Transition and Review of Strategic Alternatives
September 13, 2020
miRagen Announces Results of Meeting With FDA Regarding the Design of Pivotal Trial for Cobomarsen in ATLL
August 19, 2020
miRagen Reports Second Quarter 2020 Financial Results and Provides Business Updates
August 4, 2020
miRagen to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
August 3, 2020
miRagen, Investigators from Goethe University and University Hospital Frankfurt and Servier Publish MRG-110 Phase 1 Pharmacodynamic Biomarker Data in Nucleic Acid Therapeutics
July 27, 2020
miRagen to Report Second Quarter 2020 Financial Results on August 5, 2020
July 21, 2020
miRagen Regains Compliance With Nasdaq Listing Requirements
July 1, 2020
miRagen Announces Encouraging Preclinical Safety and Efficacy Data for its Next-generation miR-29 Replacement Product Candidate Intended for the Treatment of Idiopathic Pulmonary Fibrosis
June 21, 2020
miRagen Strengthens Leadership Team with Appointment of Lee Rauch as Chief Operating Officer
June 17, 2020
miRagen to Host a Key Opinion Leader Call on Idiopathic Pulmonary Fibrosis on Tuesday, June 23rd
June 15, 2020
miRagen to Present at the Jefferies 2020 Virtual Global Healthcare Conference
May 25, 2020
miRagen Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 6, 2020
miRagen Therapeutics to Report First Quarter 2020 Financial Results On May 7, 2020
April 22, 2020
miRagen Reports Fourth Quarter and Full Year 2019 Financial Results
March 10, 2020
miRagen Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on March 11, 2020
February 19, 2020
miRagen Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants to Purchase Common Stock
February 6, 2020
miRagen Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
February 5, 2020
miRagen Therapeutics Announces Positive Data for Cobomarsen in Adult T-Cell Leukemia/lymphoma Patients With Residual Disease
January 29, 2020
miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma at Two Upcoming Conferences
January 22, 2020
Decks in 2020
- miRagen Therapeutics — Investor Presentation (October 2020)
Investor deck · 26 slides · Oct 28, 2020